Importantly, our study demonstrates that the GATA2 inhibitor K7174 perturbs enzalutamide-liganded AR-mediated transcription activation and markedly enhances the ability of enzalutamide to decrease prostate cancer cell proliferation. The gene discussed is GATA2; the disease is prostate cancer.